| In silico design | Stable molecule | Formulation development | Market launch |
|---|
|
FGF2 for stem cell cultivation |
FGF2-STAB® (patent WO2017089016A1) |
Global distribution agreement Global license agreement |
|
FGF2 for cultured meat media |
FGF2-STAB® (patent WO2017089016A1) |
Distributors and licensing partners sought |
| FGF2 for cosmetics | FGF2-STAB® (patent WO2017089016A1) |
Licensing partners sought Product development and testing finished (supported by OPPIK – Aplikace) |
| FGF2 for veterinary medicine | FGF2-STAB® (patent WO2017089016A1) |
Licensing partners sought |
| FGF2 for wound healing | FGF2-STAB® (patent WO2017089016A1) |
Preclinical testing design (supported by Innovation Voucher) Preclinical efficacy testing (supported by Innovation Voucher) Licensing partners sought |
|
FGF10 for cultivation media |
FGF10-STAB® (patent filed) |
Global distribution agreement |
| FGF10 for lung injury/disease treatment (ALI/ARDS) | FGF10-STAB® (patent filed) |
Preclinical testing stage Licensing partners sought |
| FGF7 for cell cultivation media |
Test samples on request Licensing partners sought |
| FGF18 for osteoarthritis treatment | FGF18-STAB (patent granted) |
Test samples on request Licensing partners sought |
| FGF20 for neurodegenerative disease treatment (AD and PD) |
Test samples on request Licensing partners sought |
| FGF21 for metabolic disease treatment (obesity and diabetes) |
Test samples on request Licensing partners sought |
| More FGFs for cell culture and medical use | FGFx (3 new molecules) |
| Growth factors for cell culture, cultured meat and medical use | GFx (3 new molecules) |
Our molecules are being developed with support of:
